Responsiveness of the quality of life in late-stage dementia scale to psychotropic drug treatment in late-stage dementia

Dementia and Geriatric Cognitive Disorders

Volumn 19, Issue 2-3, 2005, Pages 82-85

  Martin Cook, Kristin ^a   Hynan, Linda S ^a   Rice Koch, Kathleen ^a   Svetlik, Doris A ^a   Weiner, Myron F ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Dementia; Psychotropic drugs; Quality of life

Indexed keywords

MOOD STABILIZER; OLANZAPINE; PSYCHOTROPIC AGENT; RISPERIDONE; BENZODIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT;

AGED; AGITATION; AIRWAY OBSTRUCTION; AKATHISIA; APHASIA; ARTICLE; BEHAVIOR; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMENTIA; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG SAFETY; DYSTONIA; EDEMA; EXTRAPYRAMIDAL SYMPTOM; FALLING; FATIGUE; FEMALE; GAIT DISORDER; GASTROINTESTINAL SYMPTOM; HUMAN; INFECTION; MALE; MUSCLE WEAKNESS; MYOCLONUS; OUTCOMES RESEARCH; PRIORITY JOURNAL; PULSE RATE; QUALITY OF LIFE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SIDE EFFECT; SKIN ABRASION; SKIN INJURY; STROKE; TARDIVE DYSKINESIA; ALZHEIMER DISEASE; COMPARATIVE STUDY; HOME FOR THE AGED; LONG TERM CARE; MENTAL HEALTH; NURSING HOME; PSYCHOLOGICAL ASPECT; PSYCHOMETRY; SOCIOPATHY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DOUBLE-BLIND METHOD; FEMALE; HOMES FOR THE AGED; HUMANS; LONG-TERM CARE; MALE; MENTAL STATUS SCHEDULE; NURSING HOMES; PSYCHOMETRICS; QUALITY OF LIFE; RISPERIDONE; SOCIAL BEHAVIOR DISORDERS;

EID: 20644447363     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000082353     Document Type: Article

References (18)

1. Guyatt GH, Veldhuyzen Van Zanten SJO, Feeny DH, Patrick DL: Measuring quality of life in clinical trials: A taxonomy and review. CMAJ 1989;140:1441-1447.
2. Wilson IB, Cleary PD: Linking clinical variables with health-related quality of life: A conceptual model of patient outcomes. JAMA 1995;273:59-65.
3. Whitehouse PJ, Orgogozo JM, Becker RE, Gauthier S, Pontecorvo M, Erzigkeit H, Rogers S, Mohs RC, Bodick N, Bruno G, Dal-Bianco P: Quality-of-life assessment in dementia drug development. Position paper from the international working group on harmonization of dementia drug guidelines. Alzheimer Dis Assoc Disord 1997;11:56-60.
4. Weiner MF: Treatment of behavioral/psychological symptoms in Alzheimer's disease. Expert Rev Neurotherapeut 2001;1:70-80.
5. Katz IR, Jeste DV, Mintzer JE, Clyde C, Napolitano J, Brecher M: Comparison of risperidone and placebo for psychosis and behavior disturbances associated with dementia: A randomized, double-blind trial. J Clin Psychiatry 1999;60:107-115.
6. Lawton MP: Assessing quality of life in Alzheimer disease research. Alzheimer Dis Assoc Disord 1997;11(suppl 6):91-99.
7. Walker MD, Salek SS, Bayer AJ: A review of quality of life in Alzheimer's disease. Pharmacoeconomics 1998;14:499-530.
8. Logsdon RG, Gibbons LE, McCurry SM, Teri L: Quality of life in Alzheimer's disease: Patient and caregiver reports. J Ment Health Aging 1999;5:21-32.
9. Albert SM, Del Castillo-Castenada C, Sano M, Jacobs DM, Marder K, Bell K, Bylsma F, Lafleche G, Brandt J, Albert M, Stern Y: Quality of life in patients with Alzheimer's disease as reported by patient proxies. J Am Geriatr Soc 1996;44:1342-1347.
10. Demers L, Oremus M, Perrault A, Champoux N, Wolfson C: Review of outcome measurement instruments in Alzheimer's disease drug trials: Psychometric properties of functional and quality of life scales. J Geriatr Psychiatry Neurol 2000;13:170-180.
11. Weiner MF, Martin-Cook K, Svetlik DA, Saine K, Foster B, Fontaine CS: The Quality of Life in Late-Stage Dementia (QUALID) Scale. J Am Med Dir Assoc 2000;1:114-116.
12. Fontaine CS, Hynan LS, Koch K, Martin-Cook K, Svetlik D, Weiner MF: A double-blind comparison of olanzapine versus risperidone in the acute treatment of dementia-related behavioral disturbances in extended care facilities. J Clin Psychiatry 2003;64:726-730.
13. Teri L, Logsdon RG, Peskind E, Raskind M, Weiner MF, Tractenberg RE, Foster NL, Schneider LS, Sano M, Whitehouse P, Tariot P, Melow AM, Auchus AP, Grundman M, Thomas RG, Schafer K, Thal LJ: Treatment of agitation in Alzheimer's disease patients: A randomized placebo-controlled clinical trial. Neurology 2000:55:1271-1278.
14. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J: The neuropsychiatric inventory: Comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308-2314.
15. Guy W: Clinical Global Impressions (CGI). ECDEU Assessment Manual for Psychopharmacology. Rockville, US Department of Health, Education, and Welfare, 1976, pp 218-222.
16. Helmes E, Csapo KG, Short JA: Standardization and validation of the Multidimensional Observational Scale for Elderly Subjects. Br J Psychiatry 1987;137:558-565.
17. Folstein MF, Folstein SE, McHugh PR: Mini-Mental State: A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
18. Simpson GM, Angus JW: A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970;212:11-19.